Literature DB >> 14561784

Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity.

Janet R McColm1, Steve Cunningham, Jean Wade, Kofi Sedowofia, Balazs Gellen, Tarun Sharma, Neil McIntosh, Brian W Fleck.   

Abstract

The aim of this study was to investigate whether the mean around which arterial oxygen fluctuations take place was important in a unique animal model of oxygen-induced retinopathy. Retinopathy of prematurity (ROP) is associated with fluctuating arterial oxygen. A recent retrospective study suggested that management of high-risk preterm infants at lower oxygen saturations was associated with less severe ROP. Rat pups were raised in a variable oxygen environment around a high (24%), normal (21%) or low (17%) mean inspired oxygen for 14 d. Rat pups raised in the high (24%) mean variable oxygen environment had more retarded retinal vascular development than did rats raised in an environment that fluctuated around 21% mean oxygen. In contrast, rats raised in a lower mean (17%) but still variable oxygen environment had no discernible retinal differences from controls raised in constant room air. Rats raised in a relatively hypoxic but variable oxygen environment develop less severe retinal vascular abnormalities than those raised in variable oxygen around higher oxygen means.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561784     DOI: 10.1203/01.PDR.0000099772.66376.02

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

1.  The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model.

Authors:  Grace Byfield; Steve Budd; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

Review 2.  Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis).

Authors:  Mary Elizabeth Hartnett
Journal:  Trans Am Ophthalmol Soc       Date:  2010-12

3.  Impact of Chronic Neonatal Intermittent Hypoxia on Severity of Retinal Damage in a Rat Model of Oxygen-Induced Retinopathy.

Authors:  Kay D Beharry; Charles L Cai; Taimur Ahmad; Sibel Guzel; Gloria B Valencia; Jacob V Aranda
Journal:  J Nat Sci       Date:  2018

4.  A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity.

Authors:  Kenneth W Wright; David Sami; Lisa Thompson; Rangasamy Ramanathan; Roy Joseph; Sonal Farzavandi
Journal:  Trans Am Ophthalmol Soc       Date:  2006

5.  Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model.

Authors:  Yuta Saito; Abhineet Uppal; Grace Byfield; Steven Budd; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

6.  Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy.

Authors:  Woo Taek Kim; Eok Soo Suh
Journal:  Korean J Ophthalmol       Date:  2010-04-06

Review 7.  [Pathogenesis of retinopathy of prematurity].

Authors:  M Heckmann
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

Review 8.  The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model.

Authors:  M Elizabeth Hartnett
Journal:  Doc Ophthalmol       Date:  2009-07-29       Impact factor: 2.379

Review 9.  The development of the rat model of retinopathy of prematurity.

Authors:  Joshua M Barnett; Susan E Yanni; John S Penn
Journal:  Doc Ophthalmol       Date:  2009-07-29       Impact factor: 2.379

10.  VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP.

Authors:  Janet R McColm; Pete Geisen; M Elizabeth Hartnett
Journal:  Mol Vis       Date:  2004-07-21       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.